NasdaqCM:IMUX

Stock Analysis Report

Executive Summary

Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis.

Snowflake

Fundamentals

Flawless balance sheet and overvalued.

Share Price & News

How has Immunic's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-7.8%

IMUX

3.1%

US Biotechs

0.07%

US Market


1 Year Return

n/a

IMUX

-1.6%

US Biotechs

8.9%

US Market

Return vs Industry: Insufficient data to determine how IMUX performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how IMUX performed against the US Market.


Shareholder returns

IMUXIndustryMarket
7 Day-7.8%3.1%0.07%
30 Day-31.9%0.2%-0.3%
90 Day-37.9%0.9%-1.6%
1 Yearn/a-0.7%-1.6%11.3%8.9%
3 Yearn/a18.9%14.7%46.3%36.8%
5 Yearn/a-1.8%-6.6%62.1%44.3%

Price Volatility Vs. Market

How volatile is Immunic's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Immunic undervalued compared to its fair value and its price relative to the market?

1.21x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IMUX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate IMUX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IMUX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: IMUX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IMUX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IMUX is good value based on its PB Ratio (1.2x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is Immunic forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

22.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Immunic has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Examine Immunic's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • Explore growth companies in the Pharmaceuticals & Biotech industry.

Past Performance

How has Immunic performed over the past 5 years?

-163.1%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: IMUX is unprofitable, and there is insufficient past data to establish if their past 5-year earnings growth rate was positive.

Accelerating Growth: Unable to compare IMUX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IMUX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (83.4%).


Return on Equity

High ROE: IMUX has a negative Return on Equity (-36.93%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: IMUX is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: IMUX is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Immunic's financial position?


Financial Position Analysis

Short Term Liabilities: IMUX's short term assets ($39.5M) exceeds its short term liabilities ($3.1M)

Long Term Liabilities: IMUX's short term assets (39.5M) exceeds its long term liabilities (41.0K)


Debt to Equity History and Analysis

Debt Level: IMUX is debt free.

Reducing Debt: IMUX has not had any debt for past 5 years.


Balance Sheet

Inventory Level: IMUX has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if IMUX's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IMUX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: IMUX has sufficient cash runway for 1.136445 years if free cash flow continues to reduce at historical rates of -45.9% each year.


Next Steps

Dividend

What is Immunic's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate IMUX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate IMUX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if IMUX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IMUX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IMUX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Immunic's salary, the management and board of directors tenure and is there insider trading?

2.8yrs

Average management tenure


CEO

Daniel Vitt (51yo)

2.8yrs

Tenure

0

Dr. Daniel Vitt, PhD has been the Chief Executive Officer of Immunic AG since January 1, 2017 and also its President. Dr. Vitt served as Managing Director of 4SC Discovery GmbH. Dr. Vitt Co-founded 4SC AG  ...


Management Age and Tenure

2.8yrs

Average Tenure

Experienced Management: IMUX's management team is considered experienced (2.8 years average tenure).


Board Age and Tenure

2.8yrs

Average Tenure

51yo

Average Age

Experienced Board: IMUX's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Daniel Vitt (51yo)

    CEO, President & Director

    • Tenure: 2.8yrs
  • Manfred Gröppel

    Co-Founder & COO

    • Tenure: 0yrs
  • Andreas Mühler (56yo)

    Co-Founder and Chief Medical Officer

    • Tenure: 0yrs
  • Hella Kohlhof

    Chief Scientific Officer

    • Tenure: 2.8yrs
  • Jessica Breu

    Manager IR and Communications

    • Tenure: 0yrs
  • Sanjay Patel

    Chief Financial Officer

    • Tenure: 0.3yrs

Board Members

  • Joerg Neermann (52yo)

    • Tenure: 3.8yrs
  • Daniel Vitt (51yo)

    CEO, President & Director

    • Tenure: 2.8yrs
  • Vincent Ossipow (51yo)

    Director

    • Tenure: 2.8yrs
  • Duane Nash (48yo)

    Chairman

    • Tenure: 0.8yrs
  • Jan Van den Bossche

    Director

    • Tenure: 2.8yrs

Company Information

Immunic, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Immunic, Inc.
  • Ticker: IMUX
  • Exchange: NasdaqCM
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$85.088m
  • Shares outstanding: 10.09m
  • Website: https://www.immunic-therapeutics.com

Number of Employees


Location

  • Immunic, Inc.
  • 11440 West Bernardo Court
  • Suite 300
  • San Diego
  • California
  • 92127
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IMUXNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDApr 2019
10VADB (Deutsche Boerse AG)YesCommon StockDEEURApr 2019

Biography

Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative coliti ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/23 00:41
End of Day Share Price2019/10/22 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.